An observational study in Hypertension, Cardiovascular Diseases and Sleep Disorder, sponsored by Uniformed Services University of the Health Sciences. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Uniformed Services University of the Health Sciences · Observational
The goal of this observational study is to learn about the long-term health of United States military service members who were injured during combat. The main questions it aims to examine are:
This study will recruit from a sample of participants in another research study called the Wounded Warrior Recovery Project (WWRP) who 1) agreed to be contacted about future research studies and 2) have a record of a combat injury within the Injury Severity Score ranges required for this study.
Participants will:
At the end of the study, participants will be asked to mail back the home sleep test and blood pressure monitors. Prepaid package materials will be provided.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's planned enrollment of 200 is close to the median of 210 across 1,359 observational studies indexed under Hypertension.
Browse Hypertension studies →Uniformed Services University of the Health Sciences is the lead sponsor of 45 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Wounded Warrior Recovery Project participants who 1) agreed to be contacted about future research studies and 2) have a record of injury within the established Injury Severity Score cutoffs for this study
Exclusion Criteria:
This group will include participants whose injury was scored as "severe" based on the recorded Injury Severity Score (ISS). Both cohorts will complete the same course of testing in this study.
This group will include participants whose injury was scored as "minimal" based on the recorded Injury Severity Score (ISS). Both cohorts will complete the same course of testing in this study.
Frequency of arrhythmias
Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the frequency of arrhythmias.
Time frame: 7 days of wear
Frequency of atrial fibrillation
Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the frequency of atrial fibrillation.
Time frame: 7 days of wear
Frequency of atrial flutter
Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the frequency of atrial flutter.
Time frame: 7 days of wear
Density of premature ventricular contractions (PVCs)
Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the density of PVCs (percentage of total heartbeats that are PVCs).
Time frame: 7 days of wear
Frequency of ventricular tachycardia
Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine the frequency of ventricular tachycardia.
Time frame: 7 days of wear
Heart rate
Readings from a 24-hour ambulatory electrocardiogram (ECG) monitor will be used to determine heart rate.
Time frame: 7 days of wear
Standard deviation of beat-to-beat intervals (SDNN)
Standard deviation of beat-to-beat intervals (SDNN) is a heart rate variability (HRV) time domain measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.
Time frame: 7 days of wear
Root mean square of successive differences (RMSSD)
Root mean square of successive differences (RMSSD) is a heart rate variability (HRV) time domain measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.
Time frame: 7 days of wear
Low frequency power
Low frequency power (LF, 0.04 - 0.15 Hz) is a heart rate variability (HRV) frequency domain measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.
Time frame: 7 days of wear
High frequency power
High frequency power (HF, 0.15 - 0.4 Hz) is a heart rate variability (HRV) frequency domain measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.
Time frame: 7 days of wear
Log-transformed QT variance (logQTv)
Log-transformed QT variance (logQTv) s a QT variability (QTV) measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.
Time frame: 7 days of wear
Beat-to-beat QT variability index (QTVI)
Beat-to-beat QT variability index (QTVI) is a QT variability (QTV) measure that will be automatically calculated for each 5-min epoch of the 24-hour ambulatory electrocardiogram (ECG) recording.
Time frame: 7 days of wear
Presence of obstructive sleep apnea
The presence of comorbid obstructive sleep apnea and/or nocturnal hypoxemia, will be evaluated with a home sleep study test device (HST) worn during the second or third study day
Time frame: One night
Presence of nocturnal hypoxemia
The presence of comorbid obstructive sleep apnea and/or nocturnal hypoxemia, will be evaluated with a home sleep study test device (HST) worn during the second or third study day
Time frame: One night
24-hour ambulatory blood pressure monitor (ABPM)
Blood pressure (diastolic and systolic) will be assessed using a 24-hour ABPM worn during the 24-hour period following the HST.
Time frame: 24 hours
High sensitivity C-reactive protein (hs-CRP)
This inflammatory marker will be measured during laboratory testing.
Time frame: Baseline
Posttraumatic Stress Disorder Checklist for Diagnostic and Statistics Manual of Mental Disorder 5 (PCL-5)
The severity of Posttraumatic Stress Disorder (PTSD) symptoms will be assessed by the PCL-5 20-question survey. Total scores range from 0 - 80, with higher scores indicating greater PTSD symptom severity.
Time frame: Baseline
8-item Patient Health Questionnaire depression scale (PHQ-8)
The severity of depressive symptoms will be measured by the eight-question PHQ-8 survey. Total scores range from 0 - 24, with with higher scores indicating greater depressive symptom severity.
Time frame: Baseline
Brief Dissociative Experience Scale (DES-B)
Severity of dissociative experiences will be assessed using the 8-item DES-B survey. Total scores range from 0 - 32, with with higher scores indicating greater dissociative experience severity.
Time frame: Baseline
Pittsburgh Sleep Quality Index (PSQI)
Participant-reported sleep characteristics will be assessed using the 19-item Pittsburgh Sleep Quality Index (PSQI). Total scores range from 0 - 21, with higher scores indicating worse sleep quality.
Time frame: Baseline
Epworth Sleepiness Scale (ESS)
Participant-reported sleep characteristics will be assessed using the 8-item Epworth Sleepiness Scale (ESS). Total scores range from 0 - 24, with higher scores indicating increased daytime sleepiness.
Time frame: Baseline
Insomnia Severity Index (ISI)
Participant-reported sleep characteristics will be assessed using the 7-item Insomnia Severity Index (ISI). Total scores range from 0 - 28, with higher scores indicating increased insomnia symptoms.
Time frame: Baseline
Berlin Sleep Questionnaire
Participant-reported sleep characteristics will be assessed using the 11-item Berlin Sleep Questionnaire. Scores will be calculated to determine if participants are "High Risk" or "Low Risk" for sleep apnea.
Time frame: Baseline
Body Mass Index
Height and weight will be measured during laboratory visit and combined to report BMI in kg/m\^2.
Time frame: Baseline
Blood Pressure
Blood pressure (diastolic and systolic) will be recorded at the time of laboratory visit
Time frame: Baseline
Hemoglobin A1C (HBA1C)
This laboratory test will be used to assess overall health outcomes.
Time frame: Baseline
Alanine aminotransferase (ALT/SGPT)
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Albumin:globulin (A:G) ratio
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Albumin, serum
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Alkaline phosphatase, serum
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Aspartate aminotransferase (AST/SGOT)
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Bilirubin, total
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Blood urea nitrogen (BUN)
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Blood urea nitrogen (BUN):creatinine ratio
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Calcium, serum
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Carbon dioxide, total
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Chloride, serum
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Creatinine, serum
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Estimated glomerular filtration rate (eGFR) calculation
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Globulin, total
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Glucose, serum
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Potassium, serum
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Protein, total, serum
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Sodium, serum
This laboratory test will be measured as part of a comprehensive metabolic panel and will be used to assess overall health outcomes.
Time frame: Baseline
Cystatin C with estimated glomerular filtration rate (eGFR)
This laboratory test will be used to assess overall health outcomes.
Time frame: Baseline
Cholesterol, total
This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.
Time frame: Baseline
High-density lipoprotein (HDL) cholesterol
This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.
Time frame: Baseline
Low-density lipoprotein (LDL) cholesterol (calculation)
This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.
Time frame: Baseline
Triglycerides
This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.
Time frame: Baseline
Very low-density lipoprotein (VLDL) cholesterol (calculation)
This laboratory test will be measured as part of a lipid panel and will be used to assess overall health outcomes.
Time frame: Baseline
Albumin/creatinine ratio, random urine
This laboratory test will be used to assess overall health outcomes.
Time frame: Baseline
N-terminal pro b-type natriuretic peptide (NT-proBNP)
This laboratory test will be used to assess overall health outcomes.
Time frame: Baseline
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Uniformed Services University of the Health Sciences